KYTX — Kyverna Therapeutics Share News
0.000.00%
Last trade - 00:00- $354.36m
- $179.94m
Brief: Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Brief: Kyverna's Kyv-101 Receives U.S. FDA Ind Clearance For Treatment-Refractory Stiff-Person Syndrome In Phase 2 Trial
Leerink initiates Kyverna coverage with 'outperform'
U.S. RESEARCH ROUNDUP-CommScope Holding Company, Dutch Bros, Hess Corp
Brief: Gilead Sciences Reports 9.6% Passive Stake In Kyverna Therapeutics As Of Feb 12, 2024
Kyverna Therapeutics surges nearly 60% after IPO upsized
Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut (updated)
Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut
Kyverna Therapeutics to raise $319 million in upsized IPO
Brief: Kyverna Therapeutics Announces Pricing Of Upsized Initial Public Offering